{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T02:18:42Z","timestamp":1787451522802,"version":"build-2736575974"},"reference-count":101,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,20]],"date-time":"2024-08-20T00:00:00Z","timestamp":1724112000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["NS133979"],"award-info":[{"award-number":["NS133979"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["NS109209"],"award-info":[{"award-number":["NS109209"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["NS121826"],"award-info":[{"award-number":["NS121826"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["NS122880"],"award-info":[{"award-number":["NS122880"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["NS099328"],"award-info":[{"award-number":["NS099328"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurobiology of Disease"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.nbd.2024.106646","type":"journal-article","created":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T23:57:53Z","timestamp":1724371073000},"page":"106646","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Interactions of alpha-synuclein with membranes in Parkinson's disease: Mechanisms and therapeutic strategies"],"prefix":"10.1016","volume":"201","author":[{"given":"Baoyi","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulf","family":"Dettmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nbd.2024.106646_bb0005","doi-asserted-by":"crossref","first-page":"3957","DOI":"10.1073\/pnas.77.7.3957","article-title":"Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent","volume":"77","author":"Alberts","year":"1980","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.nbd.2024.106646_bb0010","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.3390\/ijms24021760","article-title":"AmyP53 prevents the formation of neurotoxic \u03b2-amyloid oligomers through an UNPRECEDENT mechanism of interaction with gangliosides: insights for Alzheimer\u2019s disease therapy","volume":"24","author":"Azzaz","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.nbd.2024.106646_bb0015","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1111\/j.1471-4159.2008.05254.x","article-title":"Statins reduce neuronal \u03b1-synuclein aggregation in in vitro models of Parkinson\u2019s disease","volume":"105","author":"Bar-On","year":"2008","journal-title":"J. Neurochem."},{"key":"10.1016\/j.nbd.2024.106646_bb0020","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/nature10324","article-title":"\u03b1-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation","volume":"477","author":"Bartels","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.nbd.2024.106646_bb0025","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.neuron.2013.09.004","article-title":"The function of \u03b1-synuclein","volume":"79","author":"Bendor","year":"2013","journal-title":"Neuron"},{"key":"10.1016\/j.nbd.2024.106646_bb0030","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1073\/pnas.0407146102","article-title":"Release of long-range tertiary interactions potentiates aggregation of natively unstructured alpha-synuclein","volume":"102","author":"Bertoncini","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.nbd.2024.106646_bb0035","doi-asserted-by":"crossref","first-page":"7710","DOI":"10.1073\/pnas.0910723107","article-title":"EGCG remodels mature \u03b1-synuclein and amyloid-\u03b2 fibrils and reduces cellular toxicity","volume":"107","author":"Bieschke","year":"2010","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.nbd.2024.106646_bb0040","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1042\/BST20120096","article-title":"Bacterial in-cell NMR of human \u03b1-synuclein: a disordered monomer by nature?","volume":"40","author":"Binolfi","year":"2012","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.nbd.2024.106646_bb0045","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.neulet.2016.11.058","article-title":"Extracts from two ubiquitous Mediterranean plants ameliorate cellular and animal models of neurodegenerative proteinopathies","volume":"638","author":"Briffa","year":"2017","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.nbd.2024.106646_bb0050","doi-asserted-by":"crossref","first-page":"15610","DOI":"10.1021\/bi061743l","article-title":"\u03b1-Synuclein adopts an \u03b1-helical conformation in the presence of polyunsaturated fatty acids to hinder micelle formation","volume":"45","author":"Broersen","year":"2006","journal-title":"Biochemistry"},{"key":"10.1016\/j.nbd.2024.106646_bb0055","doi-asserted-by":"crossref","first-page":"E4274","DOI":"10.1073\/pnas.1416598111","article-title":"\u03b1-Synuclein assembles into higher-order multimers upon membrane binding to promote SNARE complex formation","volume":"111","author":"Burr\u00e9","year":"2014","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.nbd.2024.106646_bb0060","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1110\/ps.041255905","article-title":"Helix periodicity, topology, and dynamics of membrane-associated alpha-synuclein","volume":"14","author":"Bussell","year":"2005","journal-title":"Protein Sci. Publ. Protein Soc."},{"key":"10.1016\/j.nbd.2024.106646_bb0065","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1016\/j.bbamem.2013.06.026","article-title":"Mitochondrial membrane permeabilisation by amyloid aggregates and protection by polyphenols","volume":"1828","author":"Camilleri","year":"2013","journal-title":"Biochim. Biophys. Acta BBA - Biomembr."},{"key":"10.1016\/j.nbd.2024.106646_bb0070","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.7326\/M22-1438","article-title":"Oral ENT-01 targets enteric neurons to treat constipation in Parkinson disease","volume":"175","author":"Camilleri","year":"2022","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.nbd.2024.106646_bb0075","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/j.febslet.2011.03.046","article-title":"Inhibition and disaggregation of \u03b1-synuclein oligomers by natural polyphenolic compounds","volume":"585","author":"Caruana","year":"2011","journal-title":"FEBS Lett."},{"key":"10.1016\/j.nbd.2024.106646_bb0080","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.1016\/j.bbamem.2012.05.019","article-title":"Polyphenolic compounds are novel protective agents against lipid membrane damage by \u03b1-synuclein aggregates in vitro","volume":"1818","author":"Caruana","year":"2012","journal-title":"Biochim. Biophys. Acta BBA - Biomembr."},{"key":"10.1016\/j.nbd.2024.106646_bb0085","first-page":"1444","article-title":"Extract from the marine seaweed Padina pavonica protects mitochondrial biomembranes from damage by amyloidogenic peptides","volume":"26","author":"Caruana","year":"2021","journal-title":"Mol. Basel Switz."},{"key":"10.1016\/j.nbd.2024.106646_bb0090","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.nbd.2005.12.008","article-title":"Neuroprotective and neurorescue effect of black tea extract in 6-hydroxydopamine-lesioned rat model of Parkinson\u2019s disease","volume":"22","author":"Chaturvedi","year":"2006","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.nbd.2024.106646_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.jff.2019.103732","article-title":"Bioavailability enhancement of EGCG by structural modification and nano-delivery: a review","volume":"65","author":"Dai","year":"2020","journal-title":"J. Funct. Foods"},{"key":"10.1016\/j.nbd.2024.106646_bb0100","doi-asserted-by":"crossref","first-page":"9443","DOI":"10.1074\/jbc.273.16.9443","article-title":"Stabilization of alpha-synuclein secondary structure upon binding to synthetic membranes","volume":"273","author":"Davidson","year":"1998","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.nbd.2024.106646_bb0105","doi-asserted-by":"crossref","first-page":"623","DOI":"10.3389\/fnins.2018.00623","article-title":"Rationally designed variants of \u03b1-synuclein illuminate its in vivo structural properties in health and disease","volume":"12","author":"Dettmer","year":"2018","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.nbd.2024.106646_bb0110","doi-asserted-by":"crossref","first-page":"3466","DOI":"10.1093\/hmg\/ddx227","article-title":"Loss of native \u03b1-synuclein multimerization by strategically mutating its amphipathic helix causes abnormal vesicle interactions in neuronal cells","volume":"26","author":"Dettmer","year":"2017","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.nbd.2024.106646_bb0115","doi-asserted-by":"crossref","first-page":"28781","DOI":"10.1038\/srep28781","article-title":"Common molecular mechanism of amyloid pore formation by Alzheimer\u2019s \u03b2-amyloid peptide and \u03b1-synuclein","volume":"6","author":"Di Scala","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.nbd.2024.106646_bb0120","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.bbadis.2015.11.012","article-title":"Broad neutralization of calcium-permeable amyloid pore channels with a chimeric Alzheimer\/Parkinson peptide targeting brain gangliosides","volume":"1862","author":"Di Scala","year":"2016","journal-title":"Biochim. Biophys. Acta BBA - Mol. Basis Dis."},{"key":"10.1016\/j.nbd.2024.106646_bb0125","doi-asserted-by":"crossref","first-page":"13383","DOI":"10.3390\/ijms232113383","article-title":"AmyP53, a therapeutic peptide candidate for the treatment of Alzheimer\u2019s and Parkinson\u2019s disease: safety, stability, pharmacokinetics parameters and nose-to brain delivery","volume":"23","author":"Di Scala","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.nbd.2024.106646_bb0130","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S1474-4422(18)30295-3","article-title":"Global, regional, and national burden of Parkinson\u2019s disease, 1990\u20132016: a systematic analysis for the global burden of disease study 2016","volume":"17","author":"Dorsey","year":"2018","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.nbd.2024.106646_bb0135","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/nsmb.1437","article-title":"EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers","volume":"15","author":"Ehrnhoefer","year":"2008","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.nbd.2024.106646_bb0140","doi-asserted-by":"crossref","first-page":"11550","DOI":"10.3390\/ijms222111550","article-title":"Gene therapy strategy for Alzheimer\u2019s and Parkinson\u2019s diseases aimed at preventing the formation of neurotoxic oligomers in SH-SY5Y cells","volume":"22","author":"El-Battari","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.nbd.2024.106646_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.brainres.2021.147349","article-title":"Crowded organelles, lipid accumulation, and abnormal membrane tubulation in cellular models of enhanced \u03b1-synuclein membrane interaction","volume":"1758","author":"Ericsson","year":"2021","journal-title":"Brain Res."},{"key":"10.1016\/j.nbd.2024.106646_bb0150","doi-asserted-by":"crossref","first-page":"22596","DOI":"10.1039\/D0NR05285J","article-title":"Making biological membrane resistant to the toxicity of misfolded protein oligomers: a lesson from trodusquemine","volume":"12","author":"Errico","year":"2020","journal-title":"Nanoscale"},{"key":"10.1016\/j.nbd.2024.106646_bb0155","doi-asserted-by":"crossref","first-page":"32721","DOI":"10.1038\/srep32721","article-title":"Binding affinity of amyloid oligomers to cellular membranes is a generic indicator of cellular dysfunction in protein misfolding diseases","volume":"6","author":"Evangelisti","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.nbd.2024.106646_bb0160","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.molcel.2018.11.028","article-title":"Lipidomic analysis of \u03b1-synuclein neurotoxicity identifies stearoyl CoA desaturase as a target for Parkinson treatment","volume":"73","author":"Fanning","year":"2019","journal-title":"Mol. Cell"},{"key":"10.1016\/j.nbd.2024.106646_bb0165","first-page":"1","article-title":"Lipase regulation of cellular fatty acid homeostasis as a Parkinson\u2019s disease therapeutic strategy","volume":"8","author":"Fanning","year":"2022","journal-title":"Npj Park. Dis."},{"key":"10.1016\/j.nbd.2024.106646_bb0170","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.jmb.2011.03.009","article-title":"Molecular basis for the glycosphingolipid-binding specificity of \u03b1-synuclein: key role of tyrosine 39 in membrane insertion","volume":"408","author":"Fantini","year":"2011","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.nbd.2024.106646_bb0175","doi-asserted-by":"crossref","first-page":"5857","DOI":"10.1038\/ncomms6857","article-title":"Small molecule-mediated stabilization of vesicle-associated helical \u03b1-synuclein inhibits pathogenic misfolding and aggregation","volume":"5","author":"Fonseca-Ornelas","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.nbd.2024.106646_bb0180","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/nchembio.1750","article-title":"Lipid vesicles trigger \u03b1-synuclein aggregation by stimulating primary nucleation","volume":"11","author":"Galvagnion","year":"2015","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.nbd.2024.106646_bb0185","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1093\/brain\/awab371","article-title":"Sphingolipid changes in Parkinson L444P GBA mutation fibroblasts promote \u03b1-synuclein aggregation","volume":"145","author":"Galvagnion","year":"2022","journal-title":"Brain J. Neurol."},{"key":"10.1016\/j.nbd.2024.106646_bb0190","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/j.bbapap.2018.07.004","article-title":"Ganglioside lipids accelerate \u03b1-synuclein amyloid formation","volume":"1866","author":"Gaspar","year":"2018","journal-title":"Biochim. Biophys. Acta BBA - Proteins Proteomics"},{"key":"10.1016\/j.nbd.2024.106646_bb0195","doi-asserted-by":"crossref","first-page":"767","DOI":"10.3233\/JAD-2011-111061","article-title":"Identification of polyphenolic compounds and black tea extract as potent inhibitors of lipid membrane destabilization by A\u03b2 42 aggregates","volume":"27","author":"Gauci","year":"2011","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.nbd.2024.106646_bb0200","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/0896-6273(95)90040-3","article-title":"Characterization of a novel protein regulated during the critical period for song learning in the zebra finch","volume":"15","author":"George","year":"1995","journal-title":"Neuron"},{"key":"10.1016\/j.nbd.2024.106646_bb0205","doi-asserted-by":"crossref","first-page":"767","DOI":"10.3390\/biom11050767","article-title":"Green tea epigallocatechin-3-gallate (EGCG) targeting protein misfolding in drug discovery for neurodegenerative diseases","volume":"11","author":"Gon\u00e7alves","year":"2021","journal-title":"Biomolecules"},{"key":"10.1016\/j.nbd.2024.106646_bb0210","doi-asserted-by":"crossref","first-page":"33928","DOI":"10.1038\/srep33928","article-title":"Arachidonic acid mediates the formation of abundant alpha-helical multimers of alpha-synuclein","volume":"6","author":"Iljina","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.nbd.2024.106646_bb0215","doi-asserted-by":"crossref","first-page":"20760","DOI":"10.1073\/pnas.1903216116","article-title":"Cell models of lipid-rich \u03b1-synuclein aggregation validate known modifiers of \u03b1-synuclein biology and identify stearoyl-CoA desaturase","volume":"116","author":"Imberdis","year":"2019","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.nbd.2024.106646_bb0220","doi-asserted-by":"crossref","first-page":"19666","DOI":"10.1073\/pnas.0807826105","article-title":"Structure of membrane-bound alpha-synuclein from site-directed spin labeling and computational refinement","volume":"105","author":"Jao","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.nbd.2024.106646_bb0225","doi-asserted-by":"crossref","first-page":"42603","DOI":"10.1074\/jbc.M111.271130","article-title":"Membrane curvature sensing by amphipathic helices: a single liposome study using alpha-synuclein and annexin B12","volume":"286","author":"Jensen","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.nbd.2024.106646_bb0230","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1093\/hmg\/ddy105","article-title":"Acid ceramidase inhibition ameliorates \u03b1-synuclein accumulation upon loss of GBA1 function","volume":"27","author":"Kim","year":"2018","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.nbd.2024.106646_bb0235","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1093\/brain\/awy147","article-title":"Is Parkinson\u2019s disease a lysosomal disorder?","volume":"141","author":"Klein","year":"2018","journal-title":"Brain J. Neurol."},{"key":"10.1016\/j.nbd.2024.106646_bb0240","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s13024-021-00501-z","article-title":"Neuropathology and molecular diagnosis of synucleinopathies","volume":"16","author":"Koga","year":"2021","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.nbd.2024.106646_bb0245","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1007\/s12031-022-02066-y","article-title":"Prosaposin reduces \u03b1-synuclein in cells and saposin C dislodges it from glucosylceramide-enriched lipid membranes","volume":"72","author":"Kojima","year":"2022","journal-title":"J. Mol. Neurosci."},{"key":"10.1016\/j.nbd.2024.106646_bb0250","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.expneurol.2009.11.015","article-title":"Lovastatin ameliorates \u03b1-synuclein accumulation and oxidation in transgenic mouse models of \u03b1-synucleinopathies","volume":"221","author":"Koob","year":"2010","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.nbd.2024.106646_bb0255","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2024.109865","article-title":"MUFA synthesis and stearoyl-CoA desaturase as a new pharmacological target for modulation of lipid and alpha-synuclein interaction against Parkinson\u2019s disease synucleinopathy","volume":"249","author":"Kula","year":"2024","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.nbd.2024.106646_bb0260","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1021\/acschemneuro.1c00001","article-title":"Ellagic acid inhibits \u03b1-synuclein aggregation at multiple stages and reduces its cytotoxicity","volume":"12","author":"Kumar","year":"2021","journal-title":"ACS Chem. Nerosci."},{"key":"10.1016\/j.nbd.2024.106646_bb0265","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/418291a","article-title":"Amyloid pores from pathogenic mutations","volume":"418","author":"Lashuel","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.nbd.2024.106646_bb0270","series-title":"Progress in Molecular Biology and Translational Science, Gangliosides in Health and Disease","first-page":"435","article-title":"Chapter fifteen - gangliosides, \u03b1-synuclein, and Parkinson\u2019s disease","author":"Ledeen","year":"2018"},{"key":"10.1016\/j.nbd.2024.106646_bb0275","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/s41467-018-07699-5","article-title":"Trodusquemine enhances A\u03b242 aggregation but suppresses its toxicity by displacing oligomers from cell membranes","volume":"10","author":"Limbocker","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.nbd.2024.106646_bb0280","doi-asserted-by":"crossref","first-page":"4542","DOI":"10.3390\/ijms21124542","article-title":"Rationally designed antibodies as research tools to study the structure\u2013toxicity relationship of amyloid-\u03b2 oligomers","volume":"21","author":"Limbocker","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.nbd.2024.106646_bb0285","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s42003-020-01140-8","article-title":"Trodusquemine displaces protein misfolded oligomers from cell membranes and abrogates their cytotoxicity through a generic mechanism","volume":"3","author":"Limbocker","year":"2020","journal-title":"Commun. Biol."},{"key":"10.1016\/j.nbd.2024.106646_bb0290","first-page":"15","article-title":"Squalamine and its derivatives modulate the aggregation of amyloid-\u03b2 and \u03b1-synuclein and suppress the toxicity of their oligomers","author":"Limbocker","year":"2021","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.nbd.2024.106646_bb0295","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1006\/scdb.1998.0275","article-title":"Perilipins, ADRP, and other proteins that associate with intracellular neutral lipid droplets in animal cells","volume":"10","author":"Londos","year":"1999","journal-title":"Semin. Cell Dev. Biol."},{"key":"10.1016\/j.nbd.2024.106646_bb0300","doi-asserted-by":"crossref","first-page":"21299","DOI":"10.1074\/jbc.M114.554667","article-title":"How epigallocatechin gallate can inhibit \u03b1-synuclein oligomer toxicity in vitro","volume":"289","author":"Lorenzen","year":"2014","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.nbd.2024.106646_bb0305","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/0169-328X(91)90043-W","article-title":"The rat brain synucleins; family of proteins transiently associated with neuronal membrane","volume":"11","author":"Maroteaux","year":"1991","journal-title":"Brain Res. Mol. Brain Res."},{"key":"10.1016\/j.nbd.2024.106646_bb0310","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1523\/JNEUROSCI.08-08-02804.1988","article-title":"Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal","volume":"8","author":"Maroteaux","year":"1988","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nbd.2024.106646_bb0315","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.cell.2011.06.001","article-title":"Gaucher disease glucocerebrosidase and \u03b1-synuclein form a bidirectional pathogenic loop in synucleinopathies","volume":"146","author":"Mazzulli","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.nbd.2024.106646_bb0320","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1093\/brain\/awu020","article-title":"Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells","volume":"137","author":"McNeill","year":"2014","journal-title":"Brain"},{"key":"10.1016\/j.nbd.2024.106646_bb0325","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2023.108419","article-title":"Targeting the GBA1 pathway to slow Parkinson disease: insights into clinical aspects, pathogenic mechanisms and new therapeutic avenues","volume":"246","author":"Menozzi","year":"2023","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.nbd.2024.106646_bb0330","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1016\/j.bpj.2010.07.056","article-title":"Effects of curvature and composition on alpha-synuclein binding to lipid vesicles","volume":"99","author":"Middleton","year":"2010","journal-title":"Biophys. J."},{"key":"10.1016\/j.nbd.2024.106646_bb0335","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1001\/jamaneurol.2019.4611","article-title":"Ambroxol for the treatment of patients with Parkinson disease with and without glucocerebrosidase gene mutations: a nonrandomized, noncontrolled trial","volume":"77","author":"Mullin","year":"2020","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.nbd.2024.106646_bb0340","first-page":"8","article-title":"SCD inhibition protects from \u03b1-synuclein-induced neurotoxicity but is toxic to early neuron cultures","author":"Nicholatos","year":"2021","journal-title":"eNeuro"},{"key":"10.1016\/j.nbd.2024.106646_bb0345","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1002\/ana.25920","article-title":"A stearoyl\u2013coenzyme A desaturase inhibitor prevents multiple parkinson disease phenotypes in \u03b1-synuclein mice","volume":"89","author":"Nuber","year":"2021","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.nbd.2024.106646_bb0350","first-page":"1018","article-title":"A brain-penetrant stearoyl-CoA desaturase inhibitor reverses \u03b1-synuclein toxicity","volume":"19","author":"Nuber","year":"2022","journal-title":"Neurother. J. Am. Soc. Exp. Neurother."},{"key":"10.1016\/j.nbd.2024.106646_bb0355","doi-asserted-by":"crossref","first-page":"21966","DOI":"10.1074\/jbc.M401076200","article-title":"\u03b1-Synuclein has a high affinity for packing defects in a bilayer membrane","volume":"279","author":"Nuscher","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.nbd.2024.106646_bb0360","doi-asserted-by":"crossref","first-page":"E1009","DOI":"10.1073\/pnas.1610586114","article-title":"A natural product inhibits the initiation of \u03b1-synuclein aggregation and suppresses its toxicity","volume":"114","author":"Perni","year":"2017","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.nbd.2024.106646_bb0365","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1021\/acschembio.8b00466","article-title":"Multistep inhibition of \u03b1-synuclein aggregation and toxicity in vitro and in vivo by trodusquemine","volume":"13","author":"Perni","year":"2018","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.nbd.2024.106646_bb0370","doi-asserted-by":"crossref","first-page":"41958","DOI":"10.1074\/jbc.M105022200","article-title":"Exposure to long chain polyunsaturated fatty acids triggers rapid multimerization of synucleins","volume":"276","author":"Perrin","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.nbd.2024.106646_bb0375","doi-asserted-by":"crossref","first-page":"3630","DOI":"10.3390\/ijms20153630","article-title":"Function of green tea catechins in the brain: epigallocatechin gallate and its metabolites","volume":"20","author":"Pervin","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.nbd.2024.106646_bb0380","doi-asserted-by":"crossref","first-page":"16165","DOI":"10.1038\/s41598-018-34490-9","article-title":"The small molecule alpha-synuclein misfolding inhibitor, NPT200-11, produces multiple benefits in an animal model of Parkinson\u2019s disease","volume":"8","author":"Price","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.nbd.2024.106646_bb0385","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1038\/s41467-023-37561-2","article-title":"Genipin prevents alpha-synuclein aggregation and toxicity by affecting endocytosis, metabolism and lipid storage","volume":"14","author":"Rosado-Ramos","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.nbd.2024.106646_bb0390","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jns.2012.10.024","article-title":"A randomized, controlled, delayed start trial of GM1 ganglioside in treated Parkinson\u2019s disease patients","volume":"324","author":"Schneider","year":"2013","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.nbd.2024.106646_bb0395","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2201910120","article-title":"High-resolution structural information of membrane-bound \u03b1-synuclein provides insight into the MoA of the anti-Parkinson drug UCB0599","volume":"120","author":"Schwarz","year":"2023","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.nbd.2024.106646_bb0400","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/S0005-2736(97)00265-4","article-title":"The aminosterol antibiotic squalamine permeabilizes large unilamellar phospholipid vesicles","volume":"1370","author":"Selinsky","year":"1998","journal-title":"Biochim. Biophys. Acta BBA - Biomembr."},{"key":"10.1016\/j.nbd.2024.106646_bb0405","doi-asserted-by":"crossref","first-page":"49874","DOI":"10.1074\/jbc.M309127200","article-title":"Altered fatty acid composition of dopaminergic neurons expressing \u03b1-synuclein and human brains with \u03b1-synucleinopathies","volume":"278","author":"Sharon","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.nbd.2024.106646_bb0410","doi-asserted-by":"crossref","first-page":"3030","DOI":"10.1039\/D2SC05534A","article-title":"Drug repurposing screens identify compounds that inhibit \u03b1-synuclein oligomers\u2019 membrane disruption and block antibody interactions","volume":"14","author":"Somavarapu","year":"2023","journal-title":"Chem. Sci."},{"key":"10.1016\/j.nbd.2024.106646_bb0415","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1093\/aje\/kwm338","article-title":"Differential effects of black versus green tea on risk of Parkinson\u2019s disease in the Singapore Chinese health study","volume":"167","author":"Tan","year":"2008","journal-title":"Am. J. Epidemiol."},{"key":"10.1016\/j.nbd.2024.106646_bb0420","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1007\/s12035-021-02695-1","article-title":"Non-clinical pharmacology of YTX-7739: a clinical stage stearoyl-CoA desaturase inhibitor being developed for Parkinson\u2019s disease","volume":"59","author":"Tardiff","year":"2022","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.nbd.2024.106646_bb0425","doi-asserted-by":"crossref","DOI":"10.1038\/nature16531","article-title":"Structural disorder of monomeric \u03b1-synuclein persists in mammalian cells","author":"Theillet","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.nbd.2024.106646_bb0430","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1523\/JNEUROSCI.1881-21.2022","article-title":"Pathogenic mechanisms of cytosolic and membrane-enriched \u03b1-synuclein converge on fatty acid homeostasis","volume":"42","author":"Tripathi","year":"2022","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nbd.2024.106646_bb0435","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1016\/j.febslet.2015.08.013","article-title":"Cholesterol facilitates interactions between \u03b1-synuclein oligomers and charge-neutral membranes","volume":"589","author":"van Maarschalkerweerd","year":"2015","journal-title":"FEBS Lett."},{"key":"10.1016\/j.nbd.2024.106646_bb0440","doi-asserted-by":"crossref","first-page":"334","DOI":"10.2174\/138920310791330659","article-title":"Membrane interactions of oligomeric alpha-synuclein: potential role in Parkinson\u2019s disease","volume":"11","author":"van Rooijen","year":"2010","journal-title":"Curr. Protein Pept. Sci."},{"key":"10.1016\/j.nbd.2024.106646_bb0445","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1016\/j.celrep.2018.11.028","article-title":"Inhibiting stearoyl-CoA desaturase ameliorates \u03b1-synuclein cytotoxicity","volume":"25","author":"Vincent","year":"2018","journal-title":"Cell Rep."},{"key":"10.1016\/j.nbd.2024.106646_bb0450","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1016\/j.jmb.2006.12.044","article-title":"Relationships between the sequence of \u03b1-synuclein and its membrane affinity, fibrillization propensity, and yeast toxicity","volume":"366","author":"Volles","year":"2007","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.nbd.2024.106646_bb0455","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1007\/s00401-013-1114-9","article-title":"Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson\u2019s disease","volume":"125","author":"Wagner","year":"2013","journal-title":"Acta Neuropathol. (Berl.)"},{"key":"10.1016\/j.nbd.2024.106646_bb0460","doi-asserted-by":"crossref","first-page":"13709","DOI":"10.1021\/bi961799n","article-title":"NACP, a protein implicated in Alzheimer\u2019s disease and learning, is natively unfolded","volume":"35","author":"Weinreb","year":"1996","journal-title":"Biochemistry"},{"key":"10.1016\/j.nbd.2024.106646_bb0465","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1016\/j.febslet.2013.06.034","article-title":"Membrane bound \u03b1-synuclein is fully embedded in the lipid bilayer while segments with higher flexibility remain","volume":"587","author":"Wietek","year":"2013","journal-title":"FEBS Lett."},{"key":"10.1016\/j.nbd.2024.106646_bb0470","doi-asserted-by":"crossref","first-page":"3217","DOI":"10.1093\/brain\/aww238","article-title":"A de novo compound targeting \u03b1-synuclein improves deficits in models of Parkinson\u2019s disease","volume":"139","author":"Wrasidlo","year":"2016","journal-title":"Brain J. Neurol."},{"key":"10.1016\/j.nbd.2024.106646_bb0475","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1002\/jnr.23090","article-title":"Deficiency of ganglioside GM1 correlates with Parkinson\u2019s disease in mice and humans","volume":"90","author":"Wu","year":"2012","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.nbd.2024.106646_bb0700","unstructured":"www.alzforum.org\/therapeutics\/ytx-7739; accessed on September 20, 2024."},{"key":"10.1016\/j.nbd.2024.106646_bb0480","doi-asserted-by":"crossref","first-page":"17945","DOI":"10.1038\/s41598-017-18349-z","article-title":"EGCG-mediated protection of the membrane disruption and cytotoxicity caused by the \u2018active oligomer\u2019 of \u03b1-synuclein","volume":"7","author":"Yang","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.nbd.2024.106646_bb0485","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2023.123194","article-title":"EGCG attenuates \u03b1-synuclein protofibril-membrane interactions and disrupts the protofibril","volume":"230","author":"Yang","year":"2023","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.nbd.2024.106646_bb0490","doi-asserted-by":"crossref","first-page":"7161","DOI":"10.1021\/bi401191v","article-title":"Saposin C protects glucocerebrosidase against \u03b1-synuclein inhibition","volume":"52","author":"Yap","year":"2013","journal-title":"Biochemistry"},{"key":"10.1016\/j.nbd.2024.106646_bb0500","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/sj.ijo.0801599","article-title":"A spermine-coupled cholesterol metabolite from the shark with potent appetite suppressant and antidiabetic properties","volume":"25","author":"Zasloff","year":"2001","journal-title":"Int. J. Obes. (Lond)"},{"key":"10.1016\/j.nbd.2024.106646_bb0505","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2020.153316","article-title":"The pharmacological activity of epigallocatechin-3-gallate (EGCG) on Alzheimer\u2019s disease animal model: a systematic review","volume":"79","author":"Zhang","year":"2020","journal-title":"Phytomedicine"}],"container-title":["Neurobiology of Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969996124002468?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969996124002468?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T05:45:17Z","timestamp":1786081517000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0969996124002468"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":101,"alternative-id":["S0969996124002468"],"URL":"https:\/\/doi.org\/10.1016\/j.nbd.2024.106646","relation":{},"ISSN":["0969-9961"],"issn-type":[{"value":"0969-9961","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Interactions of alpha-synuclein with membranes in Parkinson's disease: Mechanisms and therapeutic strategies","name":"articletitle","label":"Article Title"},{"value":"Neurobiology of Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nbd.2024.106646","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"106646"}}